Pancreatic Cancer Research

ResearcherChinese Academy of Medical Sciences & Peking Union Medical CollegeActive in the last 2 years

Hangxiang Wang

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0001-6370-9728; OpenAlex author ID A5019491326. Sources: OpenAlex.

Their work

Papers
3 (first author 0, last author 2)
Trials
0
Grants
0
Labs led
1
Collaborators
6
Papers, trials and grants by year

2020: 1 paper · 2021: none · 2022: 1 paper · 2023: none · 2024: none · 2025: 1 paper

Papers 3

  1. Structure-guided dual modification prodrug strategy for optimizing camptothecin delivery in pancreatic cancer chemotherapy. Last author DOI 10.1016/j.ijpharm.2025.125908↗
  2. Antihypertension Nanoblockers Increase Intratumoral Perfusion of Sequential Cytotoxic Nanoparticles to Enhance Chemotherapy Efficacy against Pancreatic Cancer. Co-author DOI 10.1002/advs.202201931↗
  3. Self-Assembled Gemcitabine Prodrug Nanoparticles Show Enhanced Efficacy against Patient-Derived Pancreatic Ductal Adenocarcinoma. Last author DOI 10.1021/acsami.9b16209↗

Closest collaborators

The 6 strongest of 6 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Yijie Wang · 1 shared paper, 2025 · strength 0.33
  2. Suchen Bian · 1 shared paper, 2022 · strength 0.14
  3. Penghong Song · 1 shared paper, 2022 · strength 0.14
  4. Zequn Li · 1 shared paper, 2022 · strength 0.14
  5. Shusen Zheng · 1 shared paper, 2022 · strength 0.14
  6. Liming Wu · 1 shared paper, 2020 · strength 0.13

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.